Company intelligence / Profile preview
Nordic Nanovector ASA
Oslo, Norwayprnewswire.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Phase 2
01
Overview
Nordic Nanovector developed Betalutin®, a first-in-class anti-CD37 antibody-radionuclide conjugate for relapsed/refractory non-Hodgkin lymphoma. After clinical setbacks and discontinuation of its lead program in mid/late-stage trials, the company acquired APIM Therapeutics in late 2022. The combined entity’s main asset became ATX‑101, a peptide targeting PCNA in oncology indications such as ovarian cancer and sarcoma. As of early/mid‑2024, the original pipeline has been deprioritized or discontinued.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-radionuclide conjugates (ARCs)Radioimmunotherapy (radio-labeled antibodies)Peptides (via APIM's pipeline post-merger)[7]
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Orano Med / AREVA Med – collaboration on Alpha-emitting radioimmunotherapies targeting CD37 for leukemia[8].Thor Medical AS – agreement announced June 2023 regarding radionuclide production capabilities[6].
Beyond the preview
Go deeper on Nordic Nanovector ASA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nordic Nanovector ASA.